NCCN Guidelines Add ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
Foresight Diagnostics’ ctDNA-MRD testing has been included in the NCCN Clinical Practice Guidelines for diffuse large B-cell lymphoma.
Foresight Diagnostics’ ctDNA-MRD testing has been included in the NCCN Clinical Practice Guidelines for diffuse large B-cell lymphoma.
Biodesix recently announced the inclusion of its VeriStrat profiling test in updated evidence-based, consensus-driven NCCN Guidelines for managing non-small-cell lung cancer.